Eagle Pharmaceuticals Stock Price To Earning
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Eagle Pharmaceuticals fundamentals help investors to digest information that contributes to Eagle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eagle Pink Sheet. The fundamental analysis module provides a way to measure Eagle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eagle Pharmaceuticals pink sheet.
Eagle |
Eagle Pharmaceuticals Company Price To Earning Analysis
Eagle Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Eagle Pharmaceuticals Price To Earning | 40.52 X |
Most of Eagle Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eagle Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Eagle Pharmaceuticals has a Price To Earning of 40.52 times. This is 56.81% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 41.09% lower than that of the firm.
Eagle Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eagle Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eagle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics of similar companies.Eagle Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Eagle Fundamentals
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X | ||||
| Price To Book | 0.10 X | ||||
| Price To Sales | 0.11 X | ||||
| Revenue | 316.61 M | ||||
| Gross Profit | 221.67 M | ||||
| EBITDA | 65.48 M | ||||
| Net Income | (2.67 M) | ||||
| Cash And Equivalents | 36.56 M | ||||
| Cash Per Share | 2.75 X | ||||
| Total Debt | 62.47 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 1.78 X | ||||
| Book Value Per Share | 19.25 X | ||||
| Cash Flow From Operations | 30.8 M | ||||
| Short Ratio | 3.91 X | ||||
| Earnings Per Share | 0.85 X | ||||
| Price To Earnings To Growth | 0.91 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 134 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 27.73 M | ||||
| Total Asset | 406.16 M | ||||
| Retained Earnings | 111.5 M | ||||
| Working Capital | 77.67 M | ||||
| Current Asset | 119.05 M | ||||
| Current Liabilities | 35.45 M | ||||
| Net Asset | 406.16 M |
About Eagle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eagle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eagle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eagle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |